Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.
Drug developers look to external labs to do all manners of tests, but they can easily get stretched too thin when trying to manage myriad vendors. Covance is kicking off an external lab management offering, promising to save its clients as much as 65% in oversight costs.
After a booming 2012, the CRO industry is likely to grow even further, one analyst projects, riding an increase in biotech funding and drug development successes.
After years of regulatory woes and drug shortages, Boehringer Ingelheim is calling it quits for Ben Venue, planning to shut down its contract manufacturing arm by year's end and lay off about 1,100 workers.
Fresh off making its U.S. landfall, British CRO TranScrip Partners has expanded into Hong Kong, bringing its development and marketing services to Asia.
AMRI has signed a long-term contract with the U.K.'s defense department, agreeing to take an investigational drug to Phase I with a chance to re-up once there.
Counting on a boom in the Asian demand for injectables, contract manufacturer West Pharmaceutical Services has opened the doors on a nearly 40,000-square-foot facility.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
While drug developers have been outsourcing studies in China for years, the country's fast-growing local market has created a need for in-China, for-China services. That's why CRO giant Parexel has launched Dĭng Huī, a Beijing-headquartered offshoot dedicated to helping clients get their therapies on the Chinese market.
Canadian CRO JSS has bought LatAm Clinical Trials, a Colombian-headquartered provider of Phase I-IV services across the Andes.
CRO inVentiv Health has launched a crowdsourced physician network, signing up doctors interested in late-stage research to speed the recruitment process for trial sponsors.
Private equity giant KKR has finally a sealed a deal more than $1.3 billion in the making, closing its acquisitions of PRA and ReSearch Pharmaceutical Services to create what it says is the world's fourth-largest CRO.
Contract manufacturer Capsugel is pouring millions into three facilities around the world, looking to bolster its bandwidth in soft gelatin and liquid-fill hard capsules.
PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.
Quintiles has finalized a deal for CRO Novella Clinical, snapping up its client base of emerging drug and device developers.
U.K. contract manufacturer Aesica is counting on a bullish market for solid dose diabetes drugs, and the company has poured $48 million into one of its plants to meet the demand.
Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.
CRO inVentiv Health has struck up two deals to expand its offerings, launching a policy-focused joint venture and a partnership aimed at clinical trial site selection.
Indiana-headquartered CRO Harlan Laboratories has expanded its specialty research production facility in Southern Europe, offering contract breeding service for sponsors who need animal models for clinical trials.